← Browse by Condition
Medical Condition
mesothelioma
Total Trials
7
Recruiting Now
7
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 2
ClinicalMetric tracks all active clinical trials for mesothelioma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Frequently Asked Questions — mesothelioma Clinical Trials
How many clinical trials are currently recruiting for mesothelioma?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for mesothelioma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for mesothelioma?
mesothelioma research spans Phase 1 (3 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a mesothelioma clinical trial?
Eligibility criteria for mesothelioma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 3
Phase 2 3
Top Sponsors
2 trials
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06051695 Phase 1, Phase 2
Recruiting
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Enrollment
474 pts
Location
United States
Sponsor
A2 Biotherapeutics Inc.
NCT04981119
Recruiting
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Enrollment
200 pts
Location
United States
Sponsor
A2 Biotherapeutics Inc.
NCT04792463
Recruiting
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Enrollment
500 pts
Location
United States
Sponsor
Mohamed Abdel-Rahman
NCT02012699
Recruiting
Integrated Cancer Repository for Cancer Research
Enrollment
999,999 pts
Location
United States
Sponsor
University of Nebraska
NCT06196294 Phase 1
Recruiting
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
Enrollment
30 pts
Location
China
Sponsor
Second Affiliated Hospital of ...
NCT06057935 Phase 2
Recruiting
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Enrollment
64 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
NCT05932199 Phase 1, Phase 2
Recruiting
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Enrollment
52 pts
Location
United States
Sponsor
Baylor College of Medicine
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology